Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial

Author： Park Byeong-Bae   Kim Won   Eom Hyeon   Kim Jin   Lee Young   Oh Suk   Lee Dae   Suh Cheolwon  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.1, 2011-02, pp. : 154-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aggressive Non-Hodgkin’s Lymphoma: Economics of High-Dose Therapy

By Beard S.M.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 207-224

Adis International

Access to resources Recommend Favorite

Treatment advances in non-Hodgkin’s lymphoma

By Tan B.R.   Bartlett N.L.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 451-465

Informa Healthcare

Access to resources Recommend Favorite

Economic assessment in the management of non-Hodgkin’s lymphoma

By van Agthoven Michel   Uyl-de Groot Carin A   Sonneveld Pieter   Hagenbeek Anton  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2529-2548

Informa Healthcare

Access to resources Recommend Favorite

The role of pixantrone in the treatment of non-Hodgkin’s lymphoma

By Borchmann Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 8, 2005-08 ,pp. : 1055-1061

Informa Healthcare

Access to resources Recommend Favorite

Gallium nitrate for the treatment of non-Hodgkin’s lymphoma

By Chitambar Christopher R  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 5, 2004-05 ,pp. : 531-541

Informa Healthcare

Access to resources Recommend Favorite